Angiodynamics (ANGO) Shares Outstanding (Weighted Average) (2010 - 2026)

Angiodynamics has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $41.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 1.93% year-over-year to $41.6 million; the trailing twelve-month figure through Feb 2026 stood at $41.6 million (up 1.93% YoY), and the FY2025 full-year result was $40.9 million, up 1.67% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $41.6 million, roughly flat from $41.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $41.6 million in Q1 2026, with the low at $39.0 million in Q2 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $40.2 million across 5 years, with a median of $40.1 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) rose 1.07% — and 2024, when it increased 2.23%.
• Angiodynamics' Shares Outstanding (Weighted Average) stood at $39.4 million in 2022, then increased by 1.61% to $40.0 million in 2023, then climbed by 2.23% to $40.9 million in 2024, then gained by 1.52% to $41.5 million in 2025, then grew by 0.13% to $41.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $41.6 million (Q1 2026), $41.5 million (Q4 2025), and $41.2 million (Q3 2025), per Business Quant data.